Highest-materiality recent filing
FibroBiologics appoints former NASA astronaut Kathleen Rubins to board; director Matt Link resigns
Matt Link resigned from the board effective July 2, 2026.
FibroBiologics closes $3M private placement; warrants could add $6M
Gross proceeds of $3.0M from sale of 4.08M shares/pre-funded warrants + warrants at $0.735/share.
FibroBiologics annual meeting approves 2026 equity plan, re-elects director
Stockholders approved the 2026 Equity and Incentive Plan with 2.62M for, 297k against; 2.06M shares available, including 2M new shares and 61,968 from prior plan.
FibroBiologics ups ATM offering to $7.5M; 71,830 shares sold to date
Increased maximum aggregate offering price under ATM facility to $7.5 million.
FibroBiologics grants stock options to four top executives at $1.38 per share
CEO Pete O'Heeron granted options for 92,410 shares; CFO, CSO, and General Counsel each granted 61,607 shares.
FibroBiologics enters $6.15M ATM offering with H.C. Wainwright
Up to $6.15M of common stock may be sold via at-the-market offering with H.C. Wainwright.
FibroBiologics regains full compliance with Nasdaq listing requirements; monitoring periods imposed
Nasdaq confirmed compliance with $2.5M stockholders' equity rule (Mar 9) and $1.00 bid price rule (Apr 17).
FibroBiologics amends bylaws to reduce stockholder quorum to one-third of voting power
Board amended Section 2.07 of Bylaws to lower quorum from majority to one-third of voting power.
FibroBiologics terminates sublease early, saves $0.8M in future rent; moves HQ to Houston
Sublease buyout agreement with United Fire & Casualty terminates sublease effective April 2, 2026, 18 months early.
FibroBiologics terminates sublease early, saves ~$0.8M in rent
Sublease for Webster, TX office terminated April 2, 2026, 18 months early; single payment of $45,108.25 resolves all rent obligations.
FibroBiologics implements 1-for-20 reverse stock split effective March 30, 2026
Reverse split ratio of 1:20; every 20 shares converted to 1 share.
FibroBiologics closes $3M public offering of common stock and warrants at $1.32/unit
Offering of 2,272,728 shares (or pre-funded warrants) plus warrants, combined price $1.32/unit; net proceeds ~$2.5M after fees.
FibroBiologics raises CFO Jason D. Davis base salary to $400,000
CFO Jason D. Davis annual base salary increased to $400,000, effective January 1, 2026.
FibroBiologics stockholders approve reverse stock split and warrant issuances
Reverse stock split approved at ratio between 1:5 and 1:30, with board discretion; 53.6M votes for, 1.3M against.
FibroBiologics receives Nasdaq delisting notice for continued MVLS non-compliance
Nasdaq notified FibroBiologics on Feb 3, 2026 that continued failure to meet the $35M MVLS minimum adds a delisting basis.
Nasdaq notified delisting on Dec 30, 2025, after 180-day cure period ended Dec 29 without compliance.
FibroBiologics raises ~$1.7M in registered direct offering at $0.33/share with warrants
Sold 5,227,275 shares at $0.33/share; gross proceeds ~$1.7M; closing expected Dec 16, 2025.
FibroBiologics raises $1.5M in registered direct offering priced at $0.335/share
Sold 4,477,614 shares at $0.335/share; gross proceeds ~$1.5M before fees.
FibroBiologics raises ~$4M in registered direct offering paid in gold coins; redeems $3.4M note
Priced 3,540,000 shares and 8,570,203 pre-funded warrants at $0.3303/unit, gross proceeds ~$4M.
FibroBiologics receives Nasdaq MVLS deficiency notice; 180-day cure period to Feb 2026
Nasdaq notified FibroBiologics on Aug 4, 2025 that its MVLS fell below the $35M minimum for continued listing.
FibroBiologics amends 8-K to disclose up to 41.4M shares issuable under SEPA with YA II PN
Maximum shares convertible from $15M promissory notes: 36,945,812 shares at $0.406/share.
FibroBiologics converts $1.4M of notes, issues 2.15M shares at ~$0.65 avg price
On June 20-27 and July 15, 2025, YA II PN converted $1.4M of Second and Third Notes into 2,154,530 common shares.
FibroBiologics receives Nasdaq bid price deficiency notice; 180 days to cure
Nasdaq notified FibroBiologics on July 1, 2025 that common stock closing bid price was below $1.00 for 30 consecutive trading days.
Third $5M tranche of $15M pre-paid advance drawn; total $15M now under SEPA with YA II PN, Ltd.
FibroBiologics stockholders approve capital stock increase and share issuance to YA II PN
Authorized capital stock increased via amendment to certificate of incorporation effective June 12, 2025.
FibroBiologics appoints Jason D. Davis, CPA, as CFO; base salary $350k
Jason D. Davis appointed CFO effective June 9, 2025; previously CFO at Virax Biolabs, led IPO in July 2022.
FibroBiologics Interim CFO Robert Hoffman resigns effective May 14, 2025
Robert E. Hoffman resigned as Interim CFO effective May 14 to pursue another opportunity.
FibroBiologics issues shares under $15M SEPA; converts $2.9M note principal
Issued 118,991 shares as commitment fee at $2.1010/share on Jan 7, 2025.
FibroBiologics board approves 2024 incentive bonuses for CEO O'Heeron and other executives
CEO Pete O'Heeron received $390,000 non-equity incentive bonus, total compensation $1,805,199 for 2024.
FibroBiologics closes $5M second tranche of convertible note; grants CEO/CSO options
Second $5M tranche under SEPA with YA II PN (Yorkville) funded Dec 30, 2024; convertible note bears 0% interest (18% on default).
FibroBiologics secures up to $25M standby equity facility with Yorkville; first $5M funded
Yorkville advanced $5M initial tranche of $15M pre-paid convertible notes; two additional $5M tranches subject to conditions.
FibroBiologics issues 1.15M shares at $2.17, terminates GEM SPA and warrant
Sold 1,152,074 shares to GEM at $2.17/share for aggregate $2.5M.
CFO Mark Andersen resigns; Board member Robert Hoffman appointed Interim CFO
Mark Andersen resigns as CFO effective up to Nov 15, 2024; will transition duties.
FibroBiologics enters 5-year MSA with Charles River Labs for development and manufacturing services
Master Services Agreement with Charles River Laboratories effective September 19, 2024.
FibroBiologics' shareholders approve capital stock decrease, elect directors
Shareholders elected Richard Cilento and Robert Hoffman as Class I directors for terms expiring 2027; both received over 47M votes for.
FibroBiologics reports $3.9M gross proceeds from GEM equity line draw downs
On Aug 26, 2024, sold 100,000 shares at net $4.51 (10% discount), gross $451K.
FibroBiologics Amends Bylaws to Align with Universal Proxy Rules and DGCL Updates
Amended bylaws adopted June 25, 2024, clarifying procedural requirements under Rule 14a-19 universal proxy rules.
FibroBiologics pipeline update: CYWC628 pre-clinical data shows improved wound healing vs Grafix
CYWC628 multiple administration study: 69.3% wound area reduction at day 12 vs 47.13% for Grafix (p<0.05).
FibroBiologics to present MS data at ACTRIMS; phase 0/1 shows safety, no adverse events
Phase 0/1 safety trial of allogeneic HDFs in 5 MS patients: no adverse events, strong CBC/blood chemistry/ECG correlation.
FibroBiologics preclinical data: HDF spheroids cut psoriasis severity 35% in mice
Presented at 2024 Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases.
FibroBiologics announces three US patents for fibroblast technology
Patent 11,717,596 (Sevrain): Methods for cartilage repair using in vivo bioreactor.
FibroBiologics receives three Japanese patents for fibroblast therapy technology
Japan Patent Office issued patents 7333272, 7386162, and 7387603, all invented by CEO Pete O'Heeron.
FibroBiologics begins trading on Nasdaq via direct listing under ticker FBLG
Direct listing commenced January 31, 2024 on the Nasdaq Global Market.
On July 2, 2026, Matt Link notified FibroBiologics, Inc. (the “Company”) that he was resigning from the Board of Directors (the “Board”), effective as of July 2, 2026.
On July 8, 2026, the Board appointed Kathleen Rubins, Ph.D. as a Class III director of the Board, effective July 8, 2026, to serve until the expiration of her term at the 2029 annual meeting of stockholders.
On June 9, 2025, FibroBiologics, Inc. (the “Company”) announced that Jason D. Davis has been appointed as the Company’s Chief Financial Officer, effective as of June 9, 2025 (the “Effective Date”).
On May 2, 2025, Mr. Robert E. Hoffman informed FibroBiologics, Inc. (the “Company”) of his decision to voluntarily resign from his position as the Company’s Interim Chief Financial Officer, effective as of the close of business on May 14, 2025.
On October 25, 2024, Mr. Mark Andersen informed FibroBiologics, Inc. (the “Company”) of his decision to voluntarily resign from his position as the Company’s Chief Financial Officer
Max materiality 0.90 · Median 0.55 · Most common event other_material